Live Breaking News & Updates on Generation Camptothecin

WALNUT CREEK, Calif. - November 22, 2021 - (Newswire.com) Vivacitas Oncology, Inc., a privately-held oncology company focused on tough-to-treat cancers, will present its lead development candidate, AR-67, at this year's 5th Meridian Clinical Trials (MCT) conference, Nov. 22-23, 2021. ....

Tina Runk , Joseph Rubinfeld , Vivacitas Oncology Inc , Meridian Clinical Trials , Topoisomerasei Inhibitor , Glioblastoma Multiforme , Progression Free Survival , Clinical Operations , Oncology Presents Our Lead Compound , Generation Camptothecin , Walnut Creek , Vivacitas Oncology , Artificial Intelligence , Release Service , Meridian Clinical Trials Conference ,